Search
Darifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: DARUCIL® ER 15 MGIopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Categories: Compounds used in a research, industrial, or household settingProducts: PAMIRAY 370 ENJ. 50 ML 0,755 MG FLAKON, 1 ADET, PAMIRAY 370 ENJ. 100 ML 0,755 MG FLAKON, 1 ADETTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. … [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211]
Products: Trospium Chloride ERPropranolol
go.drugbank.com/drugs/DB00571ApprovedInvestigational[L6901,L6904,L6907] Propranolol was granted FDA approval on 13 November 1967.[L6904]
Products: Propranolol HCL ER, Propranolol hcl ERSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSINA EGGefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalActing in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.
Synonyms: N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamineProducts: GEFITINIB EGAmantadine
go.drugbank.com/drugs/DB00915ApprovedInvestigationalAn antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. … The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
Mixtures: Osmolex ER, Osmolex ERProducts: Osmolex EROxycodone
go.drugbank.com/drugs/DB00497ApprovedIllicitInvestigationalOxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. … for an extended period.
Mixtures: OSSICODONE E NALOXONE EG, OSSICODONE E NALOXONE EGProducts: OSSICODONE E NALOXONE EG, Xtampza ERTrimipramine
go.drugbank.com/drugs/DB00726ApprovedInvestigationalTricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties.
Synonyms: 10,11-dihydro-N,N,β-trimethyl-5H-dibenz[b,f]azepine-5-propanamineProducts: TRIMINEURIN 40 MG/ML Z EINCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Synonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamineProducts: Cyclobenzaprine HCL ER